On patient reported outcomes in adoptive cell therapy.

"Interestingly, only 6.8 % of the recently published CAR-T trials investigated PROs as a primary or secondary outcome measure,6 and none of the TIL-ACT clinical trials in solid tumors included PROs as corollary endpoints. Indeed, much of academia’s and industry’s efforts to date have been aimed at shifting the cost-effectiveness balance of these therapies by understanding biological features of efficacy (cancer target identification, T-cell product characteristics, biomarkers of response, etc), improving the manufacturing pipeline, and scalability. Surprisingly, limited efforts have been directed to understand patients’ perspectives during cell-therapy trials."

#AdoptiveCellTherapy #PatientReportedOutcomes #immunotherapy #ClinicalTrials #DrugDevelopment

https://jitc.bmj.com/content/10/12/e006082